Patients and pharmacists can now use smartphones to check biologics are genuine with a new Merck Serono tech launched to combat counterfeiters' growing interest in high-value biopharma drugs.
Novo Nordisk is reportedly searching for obesity experts to staff an R&D centre, Merck Serono gets a new CEO, and we look at the latest biopharmaceutical hires.
Strategic partnerships - always a hot-topic for CROs – are becoming almost exclusively a big issue for mid-sized biopharma, though small biopharma and large pharma companies are interested as well, Quintiles CEO Tom Pike said Monday at the Morgan Stanley...
Strategic partnerships are “flexible, cost-effective and will become the trend over the next few years,” says CRO DZS, which has signed a multi-year deal with SBI Pharmaceuticals.
Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross Muken.
Columbia Laboratories has reported strong annual results despite a fourth quarter affected by Actavis taking the manufacture of vaginal gel Crinone in-house and the “lumpiness” of Merck Serono.
CEO Tom Pike emphasised Quintiles’ credentials as a Big Pharma collaborator and highlighted personalised medicines as a key driver for the CRO at an investment conference last week.
Trust, transparency and end-to-end participation are just some of the reasons Merck Serono says its exclusive strategic partnership with Quintiles is the “first of its kind.”
Janet Woodcock is set to stay at the CDER despite rumours of her retirement, and there's a host of new appointments at Merck Serono - welcome to in-Pharmatechnologist's People on the Move.
Just days after raising more than $1B in its IPO, Quintiles announced Wednesday it signed a five-year clinical development agreement with Merck Serono.
Merck Serono says “fast progress” in its restructure programme helped double its net savings guidance for 2012 though headcount dropped by almost 2,000 with more cuts to come.
in-PharmaTechnologist.com presents its latest round up of movements in the pharma sector, including appointments at Merck Serono, Ascletis, Allon, Acura, Sangamo and ProStrakan.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Catalent, Quintiles, ACM and Premier Research.
Merck Serono has begun work on the expansion of its Swiss biotech facility, with the additional capacity being used to meet rising demand for Erbitux (cetuximab).
France-based Flamel Technologies and Merck Serono have shook hands
on a new €2m ($2.9m) deal which would see Flamel's Medusa
technology used to develop an extended-release profile of an
undisclosed therapeutic protein.
In a shock announcement at its third quarter financial results,
Merck KGaA has said it will stop its diabetes research and partner
out any current programmes.
Merck Serono's new and improved version of its blockbuster multiple
sclerosis (MS) drug Rebif (interferon beta-1a) has been approved in
the EU, providing a little added protection to the company's MS
franchise.
